APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.

Details

Ressource 1Download: file.pdf (1113.13 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_580759D1B4B0
Type
Article: article from journal or magazin.
Collection
Publications
Title
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
Journal
PLoS medicine
Author(s)
Lanoiselée H.M., Nicolas G., Wallon D., Rovelet-Lecrux A., Lacour M., Rousseau S., Richard A.C., Pasquier F., Rollin-Sillaire A., Martinaud O., Quillard-Muraine M., de la Sayette V., Boutoleau-Bretonniere C., Etcharry-Bouyx F., Chauviré V., Sarazin M., le Ber I., Epelbaum S., Jonveaux T., Rouaud O., Ceccaldi M., Félician O., Godefroy O., Formaglio M., Croisile B., Auriacombe S., Chamard L., Vincent J.L., Sauvée M., Marelli-Tosi C., Gabelle A., Ozsancak C., Pariente J., Paquet C., Hannequin D., Campion D.
Working group(s)
collaborators of the CNR-MAJ project
ISSN
1549-1676 (Electronic)
ISSN-L
1549-1277
Publication state
Published
Issued date
03/2017
Peer-reviewed
Oui
Volume
14
Number
3
Pages
e1002270
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series.
We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification.
Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.
Keywords
Adult, Age of Onset, Alzheimer Disease/diagnosis, Alzheimer Disease/genetics, Amyloid beta-Protein Precursor/genetics, Female, France, Genetic Testing, Humans, Male, Middle Aged, Mutation, Presenilin-1/genetics, Presenilin-2/genetics
Pubmed
Web of science
Open Access
Yes
Create date
23/08/2024 11:34
Last modification date
24/08/2024 6:07
Usage data